About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Researchers Suggest New Treatment for Hepatitis C Prevention

by VR Sreeraman on August 3, 2008 at 9:30 AM
Font : A-A+

 Researchers Suggest New Treatment for Hepatitis C Prevention

Researchers have suggested that using nucleoside polymerase inhibitor, R1626, along with standard hepatitis C therapy can help in treating the chronic disease.

The team found that adding the treatment to standard therapy with pegylated interpheron alpha plus ribavirin produces a synergistic antiviral effect.

Advertisement

In the study involving 104 patients with HCV genotype 1, 21 patients were given 1500 mg of R1626 twice a day along with peginterferon alpha-2a, commonly known as Pegasys.

Thirty-two patients were given 3000 mg of R1626 twice a day along with peginterferon alpha-2a and the other thirty-one received 1500 mg of R1626 twice a day along with peginterferon alpha-2a and ribavirin.
Advertisement

The rest 20 were given the standard of care treatment of peginterferon alpha-2a with ribavirin.

The research team found that after four weeks, HCV RNA was barely visible in 29 percent of the patients treated with the first treatment, 69 percent in the group receiving second treatment and 74 percent of patients receiving the third treatment.

"The results of the present study show a marked increase in antiviral effect in patients when ribavirin is added to the combination of R1626 and peginterferon alfa-2a," said the authors.

"This phase 2a study has demonstrated a potent reduction in HCV RNA by R1626 and high viral responses with up to 74 percent rapid viral response after 4 weeks of treatment.

"The strong antiviral effect between R1626, peginterferon alfa-2a and ribavirin, suggests that the dose of one or both of these agents could be lowered to improve tolerability without significantly compromising efficacy," the authors added.

Another study shows that, in patients with chronic hepatitis C, the antiviral activity increased with the dosage.

For 14 days, the patients were treated with R1626 orally at twice-daily doses of either 500 mg, 1500 mg, 3000 mg, 4500 mg, or placebo.

"The decreases in HCV RNA from baseline observed with R1626 indicates potent antiviral activity and lack of viral load rebound in the significant majority of patients following 14 days of monotherapy," the authors report.

The reports appear in the August issue of Hepatology, a journal published by John Wiley and Sons on behalf of the American Association for the Study of Liver Diseases.

Source: ANI
SRM
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Cochlear Implants may Consequently Drive Hearing Loss
E-cigarettes Use Linked to Erectile Dysfunction
Memory Loss - Can it be Recovered?
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Hepatitis A Hepatitis B Vasculitis Silent Killer Diseases Liver Aplastic Anemia Hepatitis C Hepatitis Needlestick Injuries New Treatments for Hepatitis C 

Recommended Reading
Hepatitis A
Hepatitis A is the most benign of the hepatitis viruses and usually has no long term side effects. ....
Hepatitis B
Hepatitis B is inflammation of the liver due to infection with the hepatitis B virus....
Liver Cancer - Animation
Liver is the largest organ inside the human body. It performs 500 different functions and processes ...
Aplastic Anemia
Aplastic anemia (AA) is a term that refers to a condition where the body fails to produce enough blo...
Hepatitis C
Hepatitis C is a contagious viral disease affecting the liver that is caused by the hepatitis C ......
Needlestick Injuries
A needlestick injury is a common occupational hazard that occurs when the skin has been pierced by a...
New Treatments for Hepatitis C
Until very recently, infection with the Hepatitis C Virus (HCV) had been very difficult to treat, bu...
Vasculitis
Vasculitis is an inflammation of the blood vessels of the body that can affect people of all ages; i...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use